Literature DB >> 17551304

Correlation between saliva production and quality of life measurements in head and neck cancer patients treated with intensity-modulated radiotherapy.

Rufus Scrimger1, Aliyah Kanji, Matthew Parliament, Heather Warkentin, Colin Field, Naresh Jha, John Hanson.   

Abstract

PURPOSE: To investigate the strength of correlation between measured saliva flow rates and various toxicity endpoints commonly used in head and neck cancer (HNC) treatment.
MATERIALS AND METHODS: All patients enrolled in a phase II study using intensity modulated radiotherapy (IMRT) for HNC treatment underwent whole mouth saliva flow measurements (stimulated and unstimulated). They were also assessed for salivary gland toxicity using Radiation Therapy Oncology Group (RTOG) late toxicity grading and 9 items representing patient-graded toxicities from 2 questionnaires (Xerostomia questionnaire and University of Washington quality of life). For each patient, saliva flow rates and quality of life (QOL) data were collected preradiotherapy (RT) and at 3 intervals post-RT (3, 6, and 12 months).
RESULTS: A total of 188 sets of coregistered data were obtained for 47 patients over a period of approximately 4 years. Saliva production and mean QOL dropped significantly immediately after RT, but there was a statistically significant recovery in both parameters between 3- and 12-month post-RT. By 12 months, post-RT the mean QOL scores had returned to pre-RT baseline, although mean stimulated saliva production remained 58% below baseline.
CONCLUSION: Patients with HNC treated with IMRT experienced a small drop in QOL which recovered to baseline by 12 months post-RT. There was no statistically significant correlation seen between global health-related QOL scores and stimulated saliva production rates in the post-RT period.

Entities:  

Mesh:

Year:  2007        PMID: 17551304     DOI: 10.1097/01.coc.0000258081.70643.3d

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  16 in total

1.  Intensity-modulated radiotherapy for nasopharyngeal carcinoma: improvement of the therapeutic ratio with helical tomotherapy vs segmental multileaf collimator-based techniques.

Authors:  A M Chen; C C Yang; J Marsano; T Liu; J A Purdy
Journal:  Br J Radiol       Date:  2012-01-17       Impact factor: 3.039

Review 2.  Organ-sparing radiation therapy for head and neck cancer.

Authors:  XiaoShen Wang; ChaoSu Hu; Avraham Eisbruch
Journal:  Nat Rev Clin Oncol       Date:  2011-07-26       Impact factor: 66.675

3.  Acupuncture-Like Transcutaneous Electrical Nerve Stimulation Versus Pilocarpine in Treating Radiation-Induced Xerostomia: Results of RTOG 0537 Phase 3 Study.

Authors:  Raimond K W Wong; Snehal Deshmukh; Gwen Wyatt; Stephen Sagar; Anurag K Singh; Khalil Sultanem; Phuc F Nguyen-Tân; Sue S Yom; Joseph Cardinale; Min Yao; Ian Hodson; Chance L Matthiesen; John Suh; Harish Thakrar; Stephanie L Pugh; Lawrence Berk
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-04-01       Impact factor: 7.038

4.  Parotid sparing and quality of life in long-term survivors of locally advanced head and neck cancer after intensity-modulated radiation therapy.

Authors:  Silke Tribius; Sven Haladyn; Henning Hanken; Chia-Jung Busch; Andreas Krüll; Cordula Petersen; Corinna Bergelt
Journal:  Strahlenther Onkol       Date:  2020-12-30       Impact factor: 3.621

5.  Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease.

Authors:  Jane M Fall-Dickson; Sandra A Mitchell; Susan Marden; Edward S Ramsay; Jean-Pierre Guadagnini; Tianxia Wu; Lena St John; Steven Z Pavletic
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-06       Impact factor: 5.742

6.  Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.

Authors:  Christopher M Nutting; James P Morden; Kevin J Harrington; Teresa Guerrero Urbano; Shreerang A Bhide; Catharine Clark; Elizabeth A Miles; Aisha B Miah; Kate Newbold; MaryAnne Tanay; Fawzi Adab; Sarah J Jefferies; Christopher Scrase; Beng K Yap; Roger P A'Hern; Mark A Sydenham; Marie Emson; Emma Hall
Journal:  Lancet Oncol       Date:  2011-01-12       Impact factor: 41.316

7.  Comparison of Objective Measures of Trismus and Salivation With Patient-Reported Outcomes Following Treatment for Head and Neck Cancer.

Authors:  Sallie M Long; Annu Singh; Amy L Tin; Bridget O'Hara; Marc A Cohen; Nancy Lee; David G Pfister; Tony Hung; Richard J Wong; Andrew J Vickers; Cherry L Estilo; Jennifer R Cracchiolo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2022-08-01       Impact factor: 8.961

8.  Analysis of factors influencing the development of xerostomia during intensity-modulated radiotherapy.

Authors:  Ken Randall; Jason Stevens; Juan Fernando Yepes; Marcus E Randall; Mahesh Kudrimoti; Jonathan Feddock; Jing Xi; Richard J Kryscio; Craig S Miller
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2013-03-22

9.  Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes.

Authors:  Klaudia U Hunter; Matthew Schipper; Felix Y Feng; Teresa Lyden; Mark Haxer; Carol-Anne Murdoch-Kinch; Benjamin Cornwall; Connie S Y Lee; Douglas B Chepeha; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-10-03       Impact factor: 7.038

10.  Quality of life in head and neck cancers patients: predictive factors, functional and psychosocial outcome.

Authors:  E Babin; E Sigston; M Hitier; D Dehesdin; J P Marie; O Choussy
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-01-11       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.